Major histocompatibility complex molecule and T cell receptor (MHC molecule and TCR)

Major histocompatibility complex molecules are cell-surface glycoproteins responsible for presenting peptide antigens (from pathogens or self-proteins) to T cell receptors. They are highly polymorphic, comprising Class I (present on most nucleated cells, present peptides to CD8+ T cells) and Class II (on antigen-presenting cells, present to CD4+ T cells) varieties. The T cell receptor is a transmembrane heterodimer (mainly alpha and beta chains) on T lymphocytes that recognizes peptide-MHC complexes, initiating T cell activation and adaptive immune responses. MHC and TCRs together form the fundamental axis of antigen recognition and immune specificity in vertebrates. This pairing is central to defense against pathogens, cancer surveillance, and, when dysregulated, autoimmunity and transplant rejection. MHC molecules and T cell receptors are not a single molecular entity but refer to two co-dependent protein families whose interaction underlies T cell function and immune recognition[1][2][4][5][7]. **Note:** The phrase "MHC molecules and T cell receptors" is *not* a precise single target; they are two distinct but functionally linked protein families. This is an incorrect singular designation. For structured data, each should normally be described separately as “Major histocompatibility complex molecule (MHC)” and “T cell receptor (TCR)”.

Other names

MHCTCRmajor histocompatibility complex moleculeT-cell receptorTCR complexHLA complex (for human MHC)

Modulation of TCR signaling (e.g., calcineurin inhibition by cyclosporine/tacrolimus suppresses T cell activation); Inhibition of co-stimulation (how CTLA-4-Ig drugs work); Enhancement of T cell cytotoxicity (checkpoint inhibitors block negative regulators of TCR signaling); Blocking antigen presentation (experimental, less common)